SCHEMBL4635266

SCHEMBL4635266

N#Cc1cccc(F)c1N1CC2C(N)C2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 5/20 0.47
DPP8 Q6V1X1 1/20 0.47
DPP9 Q86TI2 1/20 0.47
DPP7 Q9UHL4 1/20 0.47
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
SSTR5 P35346 3/20 0.36
CYP3A4 P08684 2/20 0.34
SSTR2 P30874 2/20 0.34
PIM2 Q9P1W9 2/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
AADAT Q8N5Z0 1/20 0.33
CUL4A Q13619 1/20 0.33
C5AR1 P21730 2/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129624 0.79 KDM4E (0.56) KDM4EALDH1A1SSTR5SSTR2CYP2C9
SCHEMBL4635272 0.76 KDM4E (0.57) DPP4DPP8DPP9DPP7KDM4E
SCHEMBL4635979 0.76 GRM1 (0.44) DPP4DPP8DPP9DPP7KDM4E
SCHEMBL5793581 0.74 KDM4E (0.50) DPP4DPP8DPP9DPP7KDM4E
SCHEMBL4635204 0.73 DPP4 (0.47) DPP4DPP8DPP9DPP7
SCHEMBL20129616 0.73 KDM4E (0.56) DPP4DPP8DPP9DPP7KDM4E
SCHEMBL20141837 0.72 ALDH1A1 (0.49) KDM4EALDH1A1CYP3A4HPGDHSD17B10
SCHEMBL4635237 0.71 DPP4 (0.47) DPP4DPP8DPP9KDM4EALDH1A1
SCHEMBL30561230 0.70 KDM4E (0.45) DPP4DPP8DPP9DPP7KDM4E
SCHEMBL30561225 0.70 KDM4E (0.45) DPP4DPP8DPP9DPP7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 DPP4 1/4885DPP8 3/4885DPP9 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.